Valuation : Alto Neuroscience, Inc.

Market Cap 1.44B 1.24B 1.16B 1.06B 1.98B 136B 2B 13.73B 5.35B 69.46B 5.4B 5.28B 224B P/E 2026 *
-13.2x
P/E 2027 * -11.9x
Enterprise Value 1.16B 997M 936M 856M 1.6B 110B 1.61B 11.07B 4.31B 55.99B 4.35B 4.26B 180B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week+0.77%
Current month+3.39%
1 month+34.14%
3 months+94.06%
6 months+81.90%
Current year+105.51%
1 week 33.98
Extreme 33.98
37.39
1 month 27
Extreme 27
37.48
Current year 13.91
Extreme 13.9121
37.48
1 year 3.41
Extreme 3.41
37.48
3 years 1.6
Extreme 1.6
37.48
5 years 1.6
Extreme 1.6
37.48
10 years 1.6
Extreme 1.6
37.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 44 2019-12-31
Chief Executive Officer 50 2019-03-24
Director of Finance/CFO 38 2022-10-31
Director TitleAgeSince
Chairman 50 2019-03-24
Director/Board Member 47 2022-03-31
Director/Board Member 67 2023-10-17
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Free

Director

26,000 0.0814%
5/14/26 Don

Chief Executive Officer

-400,000 1.2521%
5/12/26 Free

Director

10,958 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%+0.77%+913.30% - 1.44B
-0.24%-1.09%+2.00%+17.50% 50.14B
+0.77%-4.47%+431.20%+527.07% 44.85B
+1.68%+2.18%+45.22%+21.38% 43.43B
+0.23%-2.57%+7.92%+77.16% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+1.63%+8.93% - - 17.56B
-0.83%-4.08%+21.91%+121.29% 16.55B
+0.93%+0.63%+16.86%+29.29% 14.65B
-0.44%-2.33%+78.34%+41.71% 13.93B
Average +0.26%-0.66%+170.17%+110.56% 27.66B
Weighted average by Cap. +0.43%-1.12%+97.39%+129.08%

Financials

2026 *2027 *
Net sales - -
Net income -114M -97.69M -91.67M -83.87M -157M -10.73B -158M -1.08B -422M -5.48B -426M -417M -17.67B -138M -119M -112M -102M -191M -13.08B -192M -1.32B -515M -6.68B -520M -508M -21.53B
Net Debt -279M -240M -225M -206M -384M -26.36B -387M -2.66B -1.04B -13.47B -1.05B -1.02B -43.38B -365M -314M -295M -270M -503M -34.49B -507M -3.49B -1.36B -17.63B -1.37B -1.34B -56.77B
Logo Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Employees
68
Date Price Change Volume
26-09-03 US$36.64 -0.01% 109,312
26-09-02 US$36.64 +4.09% 432,780
26-09-01 US$35.20 -0.51% 350,248
26-08-31 US$35.38 +0.71% 764,115
26-08-28 US$35.13 -3.22% 246,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
36.64USD
Average target price
38.38USD
Spread / Average Target
+4.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANRO Stock